Effects of Pregnancy on the Clinical Course and Treatment Outcomes of Vogt-Koyanagi-Harada Disease

Overview

Journal Indian J Ophthalmol

Specialty Ophthalmology

Date 2024 Oct 24

PMID 39446841

Authors

Navya Cherukuri

Somasheila I Murthy

Mudit Tyagi

Affiliations

Soon will be listed here.

Abstract

Purpose: To describe the clinical course and treatment outcomes of Vogt-Koyanagi-Harada (VKH) disease during pregnancy.

Methods: This retrospective study compares the clinical course and outcomes in pregnant and nonpregnant women with VKH. All VKH patients who were pregnant at presentation or on follow up and age-matched nonpregnant female controls during the study period (2013-2022) were included. Their best-corrected visual acuity (BCVA), clinical presentations, and treatment outcomes were analyzed.

Results: Among the 532 female VKH patients, nine (1.7%) were included. Thirty nonpregnant patients were included as control. At presentation, the mean age in the study group was 26 years ± 6.48 standard deviation (SD) compared to the control group (mean 25.1 years ± 3.04). The mean BCVA was comparable between the two groups at presentation (study group 1.35 logarithm of the minimum angle of resolution [logMAR] vs. control group 0.76 logMAR; P = 0.05) and the final follow-up (study group 0.65 logMAR vs. control group 0.35 logMAR; P = 0.15). Participants with anterior segment inflammation (study group 77.7% vs. control group 70%; P = 0.65), the disease stage (early-stage VKH: study group 88.8% vs. control group 73.3%; P = 0.33), and disease exacerbation (study group 33.3% vs. control group 26.6%; P = 0.69) were all comparable between the study and control groups. Following treatment, 66.6% and 46.6% of the study and control groups, respectively, had sunset glow fundus ( P = 0.29). At the last follow-up, 44.4% and 26.6% of the study and control groups, respectively, had subretinal fibrosis ( P = 0.31).

Conclusion: Though pregnancy is an immunomodulatory state, the clinical course of VKH in pregnant patients can be similar to that of nonpregnant women and needs close monitoring and follow-up.

References

Paizis K . Immunomodulatory drugs in pregnancy and lactation. Aust Prescr. 2019; 42(3):97-101. PMC: 6594853. DOI: 10.18773/austprescr.2019.026. View

Alromaih A, Almater A, Albloushi A, Alkheraiji N, Abu El-Asrar A . Outcomes of initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease occurred during pregnancy. Int Ophthalmol. 2022; 43(1):185-195. DOI: 10.1007/s10792-022-02415-1. View

Doi M, Matsubara H, Uji Y . Vogt-Koyanagi-Harada syndrome in a pregnant patient treated with high-dose systemic corticosteroids. Acta Ophthalmol Scand. 2000; 78(1):93-6. DOI: 10.1034/j.1600-0420.2000.078001093.x. View

Vassiliadis S, Ranella A, Papadimitriou L, Makrygiannakis A, Athanassakis I . Serum levels of pro- and anti-inflammatory cytokines in non-pregnant women, during pregnancy, labour and abortion. Mediators Inflamm. 1998; 7(2):69-72. PMC: 1781827. DOI: 10.1080/09629359891199. View

Moorthy R, Inomata H, RAO N . Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995; 39(4):265-92. DOI: 10.1016/s0039-6257(05)80105-5. View

Wang C, Tian Y, Lei B, Xiao X, Ye Z, Li F . Decreased IL-27 expression in association with an increased Th17 response in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2012; 53(8):4668-75. DOI: 10.1167/iovs.12-9863. View

Abu El-Asrar A, Dosari M, Hemachandran S, Gikandi P, Al-Muammar A . Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2016; 95(1):85-90. DOI: 10.1111/aos.13189. View

Petri M . Pregnancy and Systemic Lupus Erythematosus. Best Pract Res Clin Obstet Gynaecol. 2019; 64:24-30. DOI: 10.1016/j.bpobgyn.2019.09.002. View

Ingolotti M, Schlaen B, Melo-Granados E, Ruiz Garcia H, Aguilera Partida J . Azathioprine During the First Trimester of Pregnancy in a Patient with Vogt-Koyanagi-Harada Disease: A Multimodal Imaging Follow-Up Study. Am J Case Rep. 2019; 20:300-305. PMC: 6419529. DOI: 10.12659/AJCR.914281. View

10.

Saavedra M, Sanchez A, Morales S, Angeles U, Jara L . Azathioprine during pregnancy in systemic lupus erythematosus patients is not associated with poor fetal outcome. Clin Rheumatol. 2015; 34(7):1211-6. DOI: 10.1007/s10067-015-2987-x. View

11.

Elenkov I, Wilder R, Bakalov V, Link A, Dimitrov M, Fisher S . IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J Clin Endocrinol Metab. 2001; 86(10):4933-8. DOI: 10.1210/jcem.86.10.7905. View

12.

Nohara M, Norose K, Segawa K . Vogt-Koyanagi-Harada disease during pregnancy. Br J Ophthalmol. 1995; 79(1):94-5. PMC: 505030. DOI: 10.1136/bjo.79.1.94. View

13.

Jara L, Vera-Lastra O, Miranda J, Alcala M, Alvarez-Nemegyei J . Prolactin in human systemic lupus erythematosus. Lupus. 2001; 10(10):748-56. DOI: 10.1191/096120301717164994. View

14.

Elenkov I, Hoffman J, Wilder R . Does differential neuroendocrine control of cytokine production govern the expression of autoimmune diseases in pregnancy and the postpartum period?. Mol Med Today. 1997; 3(9):379-83. DOI: 10.1016/s1357-4310(97)01089-7. View

15.

Doria A, Iaccarino L, Arienti S, Ghirardello A, Zampieri S, Rampudda M . Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases. Reprod Toxicol. 2006; 22(2):234-41. DOI: 10.1016/j.reprotox.2006.04.001. View

16.

Ting M, Vega-Tapia F, Anguita R, Cuitino L, Valenzuela R, Salgado F . Non-Infectious Uveitis and Pregnancy, is There an Optimal Treatment? Uveitis Course and Safety of Uveitis Treatment in Pregnancy. Ocul Immunol Inflamm. 2024; 32(8):1819-1831. DOI: 10.1080/09273948.2023.2296030. View

17.

Albloushi A, Alfawaz A, Al-Dahmash S, Al Owaifeer A, Alenezi S, Al-Fakhri A . Incidence, Risk Factors and Surgical Outcomes of Cataract among Patients with Uveitis in a University Referral Hospital in Riyadh, Saudi Arabia. Ocul Immunol Inflamm. 2018; 27(7):1105-1113. DOI: 10.1080/09273948.2018.1504970. View

18.

Chiam N, Lim L . Uveitis and gender: the course of uveitis in pregnancy. J Ophthalmol. 2014; 2014:401915. PMC: 3941965. DOI: 10.1155/2014/401915. View

19.

Mondkar S, Biswas J, Ganesh S . Analysis of 87 cases with Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol. 2000; 44(3):296-301. DOI: 10.1016/s0021-5155(00)00152-0. View

20.

Nakamura T, Keino H, Okada A . SUB-TENON TRIAMCINOLONE ACETONIDE INJECTION IN A PREGNANT PATIENT WITH VOGT-KOYANAGI-HARADA DISEASE. Retin Cases Brief Rep. 2016; 12(4):375-378. DOI: 10.1097/ICB.0000000000000510. View